Bayer and Dewpoint Therapeutics co-development deal for cardiovascular and gynecological diseases
Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement... Read More
Sandoz to Acquire Japanese Biz of AGI
Posted on17 Nov 2019
Comments0
Sandoz has entered into an agreement to acquire the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen... Read More
Insignt on Roche’s Up-to-$1.4Billion Promedior Acquisition
Posted on17 Nov 2019
Comments0
Roche has agreed to acquire Promedior for up to $1.4 billion. Roche’s deal will give it full rights to Promedior’s entire portfolio... Read More
Case Study: 505(b)(2) filing pathway – USFDA approval of Vumerity
Biogen, global biotechnology company, and Alkermes, global biopharmaceutical company, announced that the US Food and Drug Administration (FDA) approved Vumerity (diroximel fumarate),... Read More
Zentiva to acquire CEE pharma business of Alvogen
Czech drugmaker Zentiva has announced it will buy the Central and Eastern European business of Alvogen, for an undisclosed amount. Alvogen CEE... Read More
How much is the average ideal royalty rate in pharmaceutical and biopharmaceutical business deal?
Posted on25 Oct 2019
Comments0
Click here to view the Royalty Chart >> View now
Pharma Licensing: Explore differences between Royalty rate & Royalty base
Posted on25 Oct 2019
Comments0
Royalty rate : The appropriate royalty rate depends on numerous factors including the relative bargaining strength of the licensor and the licensee,... Read More
Takeda Divesting Select OTC and Non-core Assets of takeda to Acino
Posted on25 Oct 2019
Tagsdisinvestment in pharma business, divestiment in pharma, Divestment in pharma, Takeda, Takeda acquires shire
Comments0
Takeda Pharmaceutical Company Limited announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription... Read More
GSK to disinvest Rabipur and Encepur – vaccine for USD 1.1 billion
Posted on22 Oct 2019
Comments0
GlaxoSmithKline (GSK) will sell two travel vaccines to Bavarian Nordic for up to 955 million euros ($1.1 billion), the British firm said... Read More
S. Korea’s Mediforum acquires local pharma firms C-TRI, i-World Pharm
South Korean bio-pharma company Mediforum Co. has acquired two local pharmaceutical firms C-TRI and i-World, a move that is expected to help... Read More